Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NmCV-5 vs Menactra for Meningococcal Meningitis Prevention
NCT03964012Phase 3Completed
- Sponsor
- Serum Institute of India
- Start
- Aug 2019
- Primary completion
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of Non-Adjuvanted MCV-5 in meningococcal meningitis (2 arms), sponsored by Serum Institute of India. Primary endpoints: Seroresponse at 28 days and Geometric Mean Titres at 28 days. Started Aug 2019; status: completed.
02
Drugs
Non-Adjuvanted MCV-5
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT03964012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964012.